ATE485290T1 - Platelet adp rezeptor inhibitoren - Google Patents

Platelet adp rezeptor inhibitoren

Info

Publication number: ATE485290T1
Authority: AT; Austria
Prior art keywords: derivatives; receptor inhibitors; adp receptor; platelet adp; formulae
Prior art date: 2001-08-02

Application number

AT06015189T

Other languages

English (en)

Inventor

Robert Scarborough

Hans-Michael Jantzen

Wolin Huang

David Sedlock

Charles Marlowe

Kim Kane-Maguire

Original Assignee

Portola Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-02

Filing date

2002-07-25

Publication date

2010-11-15

2002-07-25 Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc

2010-11-15 Application granted granted Critical

2010-11-15 Publication of ATE485290T1 publication Critical patent/ATE485290T1/de

Links

108091006082 receptor inhibitors Proteins 0.000 title 1
208000007536 Thrombosis Diseases 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
VITPICOSHHCBFU-UHFFFAOYSA-N 1-sulfonylguanidine Chemical class NC(=N)N=S(=O)=O VITPICOSHHCBFU-UHFFFAOYSA-N 0.000 abstract 1
NUOFIQOYJIFSEN-UHFFFAOYSA-N 2-cyano-1-sulfonylguanidine Chemical class N#CN=C(N)N=S(=O)=O NUOFIQOYJIFSEN-UHFFFAOYSA-N 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
KWGFMMAPDMTJHX-UHFFFAOYSA-N sulfonylthiourea Chemical class SC(=N)N=S(=O)=O KWGFMMAPDMTJHX-UHFFFAOYSA-N 0.000 abstract 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D521/00—Heterocyclic compounds containing unspecified hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT06015189T 2001-08-02 2002-07-25 Platelet adp rezeptor inhibitoren ATE485290T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/920,325 US6906063B2 (en)	2000-02-04	2001-08-02	Platelet ADP receptor inhibitors

Publications (1)

Publication Number	Publication Date
ATE485290T1 true ATE485290T1 (de)	2010-11-15

Family

ID=25443563

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT06015189T ATE485290T1 (de)	2001-08-02	2002-07-25	Platelet adp rezeptor inhibitoren
AT02750339T ATE339425T1 (de)	2001-08-02	2002-07-25	Platelet adp rezeptor inhibitoren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT02750339T ATE339425T1 (de)	2001-08-02	2002-07-25	Platelet adp rezeptor inhibitoren

Country Status (11)

Country	Link
US (7)	US6906063B2 (de)
EP (3)	EP2314593B1 (de)
JP (2)	JP4648626B2 (de)
AT (2)	ATE485290T1 (de)
CA (1)	CA2468925A1 (de)
CY (1)	CY1112024T1 (de)
DE (2)	DE60214730T2 (de)
DK (1)	DK1734041T3 (de)
ES (2)	ES2354708T3 (de)
PT (1)	PT1734041E (de)
WO (1)	WO2003011872A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254336A1 (de) *	2002-11-21	2004-06-03	Merck Patent Gmbh	Carbonsäureamide
WO2005009971A1 (ja) *	2003-07-24	2005-02-03	Astellas Pharma Inc.	キノロン誘導体又はその塩
ES2334795T3 (es)	2003-10-03	2010-03-16	Portola Pharmaceuticals, Inc.	Sulfonilureas 2,4-dioxo-3-quinazolinilarilo.
KR20060113699A (ko)	2003-10-03	2006-11-02	포톨라 파마슈티컬스, 인코포레이티드	치환된 이소퀴놀리논
US7550499B2 (en) *	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1812429A4 (de) *	2004-09-29	2010-07-21	Portola Pharm Inc	Substituierte 2h-1,3-benzoxazin-4(3h)-one
BRPI0606437A (pt) *	2005-01-06	2008-03-11	Astrazeneca Ab	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
WO2006078621A2 (en) *	2005-01-19	2006-07-27	Bristol-Myers Squibb Company	2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
ES2600460T3 (es)	2005-05-10	2017-02-09	Intermune, Inc.	Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
DE602006017694D1 (de) *	2005-06-27	2010-12-02	Bristol Myers Squibb Co	C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
ATE502924T1 (de) *	2005-06-27	2011-04-15	Bristol Myers Squibb Co	Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
WO2007002634A1 (en) *	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
TW200726764A (en)	2005-06-27	2007-07-16	Bristol Myers Squibb Co	N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
KR20080039405A (ko) *	2005-07-13	2008-05-07	아스트라제네카 아베	신규한 피리딘 유사체
EP1917244A2 (de)	2005-08-24	2008-05-07	Abbott GmbH & Co. KG	Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
PT1951254E (pt) *	2005-11-03	2012-04-12	Portola Pharm Inc	[4-(6-halo-7-substituído-2,4-dioxo-1,4-di-hidro-2hquinazolin- 3-il)-fenil]-5-cloro-tiofen-2-il-sulfonilureias e formas e métodos relacionados com as mesmas
NZ572418A (en)	2006-05-05	2011-08-26	Millennium Pharm Inc	Factor xa inhibitors
EP2032548A1 (de) *	2006-06-01	2009-03-11	F.Hoffmann-La Roche Ag	Thiazolderivate
TW200815426A (en) *	2006-06-28	2008-04-01	Astrazeneca Ab	New pyridine analogues II 333
US20080032992A1 (en) *	2006-07-04	2008-02-07	Astrazeneca Ab	New Pyridine Analogues V
KR20090020712A (ko) *	2006-07-04	2009-02-26	아스트라제네카 아베	신규한 피리딘 유도체
KR20090031605A (ko) *	2006-07-04	2009-03-26	아스트라제네카 아베	신규한 피리딘 유사체
TW200811133A (en) *	2006-07-04	2008-03-01	Astrazeneca Ab	New pyridine analogues III 334
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) *	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US7834023B2 (en) *	2006-09-20	2010-11-16	Portola Pharmaceuticals, Inc.	Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7960569B2 (en) *	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
AR064864A1 (es) *	2007-01-12	2009-04-29	Astrazeneca Ab	Compuestos analogos de piridina vii 543 y composicion farmaceutica
AR064866A1 (es) *	2007-01-12	2009-04-29	Astrazeneca Ab	Analogos de piridina
CL2008000093A1 (es) *	2007-01-12	2008-08-22	Astrazeneca Ab	Compuestos derivados de piridina, inhibidores de p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de un desorden de agregacion plaquetaria.
US9604931B2 (en)	2007-01-22	2017-03-28	Gtx, Inc.	Nuclear receptor binding agents
EA026578B1 (ru)	2007-01-22	2017-04-28	ДЖиТиЭкс, ИНК.	Вещества, связывающие ядерные рецепторы
US9623021B2 (en) *	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
US7999107B2 (en)	2007-01-31	2011-08-16	Merck Sharp & Dohme Corp.	Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
US20100113391A1 (en) *	2007-04-19	2010-05-06	Astellas Pharma Inc.	Bicyclic heterocyclic compound
US20090156620A1 (en) *	2007-05-02	2009-06-18	Portola Pharmaceuticals, Inc.	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
KR101509829B1 (ko) *	2007-05-02	2015-04-06	포톨라 파마슈티컬스, 인코포레이티드	혈소판 ａｄｐ 수용체 억제제로 작용하는 화합물을 이용한 병용요법
CA2686203A1 (en)	2007-05-02	2008-11-13	Portola Pharmaceuticals, Inc.	Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
WO2008137809A2 (en) *	2007-05-02	2008-11-13	Portola Pharmaceuticals, Inc.	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
TW200902513A (en) *	2007-07-13	2009-01-16	Astrazeneca Ab	New pyridine analogues
CN102099036B (zh)	2008-06-03	2015-05-27	英特芒尼公司	用于治疗炎性疾患和纤维化疾患的化合物和方法
US8742120B2 (en) *	2009-12-17	2014-06-03	Millennium Pharmaceuticals, Inc.	Methods of preparing factor xa inhibitors and salts thereof
CN102762550B (zh) *	2009-12-17	2015-04-01	米伦纽姆医药公司	Xa因子抑制剂的盐和结晶形式
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
CN103833724A (zh) *	2012-11-20	2014-06-04	上海医药工业研究院	一种5-氯噻吩-2-甲酰氯的制备方法
CN103833771A (zh) *	2012-11-22	2014-06-04	天津滨江药物研发有限公司	作为蛋白激酶Mek抑制剂的苯并五元杂环化合物及其制备方法和用途
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
KR102727059B1 (ko)	2015-02-16	2024-11-05	더 유니버서티 어브 퀸슬랜드	설포닐우레아와 관련 화합물 및 그 용도
JP6740354B2 (ja)	2015-10-05	2020-08-12	ザトラスティーズオブコロンビアユニバーシティーインザシティーオブニューヨーク	オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
EP3634951B8 (de)	2017-06-09	2024-08-21	Zydus Lifesciences Limited	Neuartige substituierte sulfoximinverbindungen
US11370776B2 (en)	2017-07-07	2022-06-28	Inflazome Limited	Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US11465992B2 (en)	2017-07-07	2022-10-11	Inflazome Limited	Sulfonamide carboxamide compounds
RS65492B1 (sr)	2017-07-24	2024-05-31	Novartis Ag	Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
WO2019034693A1 (en)	2017-08-15	2019-02-21	Inflazome Limited	SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
US11542255B2 (en)	2017-08-15	2023-01-03	Inflazome Limited	Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
MX2020001776A (es)	2017-08-15	2020-03-24	Inflazome Ltd	Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US11623922B2 (en)	2017-10-03	2023-04-11	Inflazome Limited	Compounds
US12221434B2 (en)	2017-11-09	2025-02-11	Inflazome Limited	Sulfonamide carboxamide compounds
KR20200087759A (ko)	2017-11-09	2020-07-21	인플라좀 리미티드	신규한 설폰아마이드 카복스아마이드 화합물
IL276398B2 (en)	2018-01-31	2026-03-01	Deciphera Pharmaceuticals Llc	Combination therapy for mastocytosis
CN118416236A (zh)	2018-01-31	2024-08-02	德西费拉制药有限责任公司	治疗胃肠道间质瘤的组合疗法
EP3759077A1 (de)	2018-03-02	2021-01-06	Inflazome Limited	Neuartige verbindungen
WO2020185812A1 (en)	2019-03-11	2020-09-17	Teva Pharmaceuticals International Gmbh	Solid state forms of ripretinib
TWI878335B (zh)	2019-08-12	2025-04-01	美商迪賽孚爾製藥有限公司	治療胃腸道基質瘤方法
EP4013412B1 (de)	2019-08-12	2026-01-28	Deciphera Pharmaceuticals, LLC	Ripretinib zur behandlung gastrointestinaler stromakarzinome
WO2021048809A1 (en) *	2019-09-12	2021-03-18	Cadila Healthcare Limited	Novel substituted sulfoximine derivatives
EP4084779B1 (de)	2019-12-30	2024-10-09	Deciphera Pharmaceuticals, LLC	Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff
MX2022008103A (es)	2019-12-30	2022-09-19	Deciphera Pharmaceuticals Llc	Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
PT4426434T (pt)	2021-11-02	2025-11-24	Flare Therapeutics Inc	Agonistas inversos de pparg e suas utilizações
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE845042C (de) *	1950-07-14	1952-07-28	Basf Ag	Verfahren zur Herstellung von Sulfonylurethanen, -harnstoffen oder -carbonsaeureamiden
US3547625A (en) *	1966-08-25	1970-12-15	Int Nickel Co	Steel containing chromium molybdenum and nickel
US3847925A (en) *	1971-07-15	1974-11-12	En Nom Collectif Science Et Ci	Benzenesulfonyl semicarbazides
GB9413975D0 (en) *	1994-07-11	1994-08-31	Fujisawa Pharmaceutical Co	New heterobicyclic derivatives
US5314902A (en)	1993-01-27	1994-05-24	Monsanto Company	Urea derivatives useful as platelet aggregation inhibitors
US6268380B1 (en)	1993-02-19	2001-07-31	G. D. Searle & Co.	Urea derivatives useful as platelet aggregation inhibitors
AU6395094A (en)	1993-03-15	1994-10-11	G.D. Searle & Co.	Urea derivatives useful as platelet aggregation inhibitors
TW448161B (en)	1994-07-14	2001-08-01	Otsuka Pharma Co Ltd	Cyclic amide derivatives
JPH0881442A (ja) *	1994-07-14	1996-03-26	Otsuka Pharmaceut Co Ltd	環状アミド誘導体
US6413724B1 (en)	1996-10-28	2002-07-02	Versicor, Inc.	Solid phase and combinatorial library syntheses of fused 2,4-pyrimidinediones
JPH10195323A (ja) *	1997-01-09	1998-07-28	Nippon Paper Ind Co Ltd	新規なスルホニルグアニジン化合物及びそれを用いた感熱記録体
CA2318199A1 (en)	1998-01-15	1999-07-22	Cor Therapeutics, Inc.	Platelet adp receptor inhibitors
JP2000204081A (ja) *	1998-02-05	2000-07-25	Takeda Chem Ind Ltd	スルホンアミド誘導体、その製造法及び用途
WO2001057037A1 (en) *	2000-02-04	2001-08-09	Cor Therapeutics, Inc.	Platelet adp receptor inhibitors
RU2319699C2 (ru) *	2001-06-20	2008-03-20	Дайити Санкио Компани, Лимитед	Производные диаминов

2001
- 2001-08-02 US US09/920,325 patent/US6906063B2/en not_active Expired - Fee Related
2002
- 2002-07-25 EP EP10183633.6A patent/EP2314593B1/de not_active Expired - Lifetime
- 2002-07-25 PT PT06015189T patent/PT1734041E/pt unknown
- 2002-07-25 ES ES06015189T patent/ES2354708T3/es not_active Expired - Lifetime
- 2002-07-25 ES ES02750339T patent/ES2272742T3/es not_active Expired - Lifetime
- 2002-07-25 DE DE60214730T patent/DE60214730T2/de not_active Expired - Lifetime
- 2002-07-25 DE DE60238086T patent/DE60238086D1/de not_active Expired - Lifetime
- 2002-07-25 AT AT06015189T patent/ATE485290T1/de active
- 2002-07-25 AT AT02750339T patent/ATE339425T1/de not_active IP Right Cessation
- 2002-07-25 JP JP2003517063A patent/JP4648626B2/ja not_active Expired - Fee Related
- 2002-07-25 CA CA002468925A patent/CA2468925A1/en not_active Abandoned
- 2002-07-25 DK DK06015189.1T patent/DK1734041T3/da active
- 2002-07-25 WO PCT/US2002/023909 patent/WO2003011872A1/en not_active Ceased
- 2002-07-25 EP EP02750339A patent/EP1412364B1/de not_active Expired - Lifetime
- 2002-07-25 EP EP06015189A patent/EP1734041B1/de not_active Expired - Lifetime
2004
- 2004-09-13 US US10/941,053 patent/US7056926B2/en not_active Expired - Lifetime
2005
- 2005-12-01 US US11/293,026 patent/US7358257B2/en not_active Expired - Fee Related
2007
- 2007-08-20 US US11/841,711 patent/US7622474B2/en not_active Expired - Fee Related
2009
- 2009-09-14 US US12/559,389 patent/US8067428B2/en not_active Expired - Fee Related
2010
- 2010-03-29 JP JP2010076428A patent/JP2010155860A/ja active Pending
2011
- 2011-01-07 CY CY20111100028T patent/CY1112024T1/el unknown
- 2011-10-10 US US13/270,193 patent/US8524721B2/en not_active Expired - Fee Related
2013
- 2013-07-31 US US13/956,251 patent/US20140221405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP4648626B2 (ja)	2011-03-09
US20100234350A1 (en)	2010-09-16
EP2314593A1 (de)	2011-04-27
HK1096088A1 (en)	2007-05-25
US20050228029A1 (en)	2005-10-13
JP2010155860A (ja)	2010-07-15
HK1064099A1 (en)	2005-01-21
ES2354708T3 (es)	2011-03-17
EP1412364A1 (de)	2004-04-28
US6906063B2 (en)	2005-06-14
US20120149688A1 (en)	2012-06-14
DE60214730T2 (de)	2007-09-06
EP1734041B1 (de)	2010-10-20
US7358257B2 (en)	2008-04-15
DK1734041T3 (da)	2011-01-24
EP2314593B1 (de)	2016-05-04
US7056926B2 (en)	2006-06-06
ATE339425T1 (de)	2006-10-15
EP1734041A3 (de)	2007-01-24
DE60238086D1 (de)	2010-12-02
US20060194795A1 (en)	2006-08-31
HK1157331A1 (en)	2012-06-29
US20020077486A1 (en)	2002-06-20
ES2272742T3 (es)	2007-05-01
US8067428B2 (en)	2011-11-29
EP1734041A2 (de)	2006-12-20
PT1734041E (pt)	2011-01-25
WO2003011872A1 (en)	2003-02-13
US20080194597A1 (en)	2008-08-14
US8524721B2 (en)	2013-09-03
US7622474B2 (en)	2009-11-24
JP2005504035A (ja)	2005-02-10
CY1112024T1 (el)	2015-11-04
DE60214730D1 (de)	2006-10-26
US20140221405A1 (en)	2014-08-07
CA2468925A1 (en)	2003-02-13
EP1412364B1 (de)	2006-09-13

Legal Events

Date

Code

Title

Description

2011-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1734041

Country of ref document: EP

Publication	Publication Date	Title
DE60238086D1 (de)	2010-12-02	Platelet adp rezeptor inhibitoren
DE60114994D1 (de)	2005-12-22	Blutplättchen-adp-rezeptor-inhibitoren
HK1050008A1 (zh)	2003-06-06	杂双环磺胺剂及以其作为血小板腺苷二磷酸(adp)受体抑制剂
DK1487444T3 (da)	2010-04-12	Anvendelse af pyridylamider som angiogeneseinhibitorer
DE60324544D1 (de)	2008-12-18	Muskarin antagonisten
PL369108A1 (en)	2005-04-18	17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60330187D1 (de)	2009-12-31	Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
NO20032233L (no)	2003-05-16	Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
ATE361288T1 (de)	2007-05-15	N-(3,-dimethylindolin-6-yl)ä2-ä(4-
ATE371656T1 (de)	2007-09-15	Heteroaryl-pyrimidinderivate als jak-inhibitoren
DK0705254T3 (da)	1999-01-25	Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
NO2007010I2 (no)	2009-12-14	Sitagliptin, eventuelt i form av et farmasøytisk akseptabelt salt
CY1108367T1 (el)	2014-02-12	Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
EA200500814A1 (ru)	2006-02-24	Производные пирролопиримидина
DE602004018338D1 (de)	2009-01-22	Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ITRM990338A0 (it)	1999-05-28	Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria.
EA200801245A1 (ru)	2008-10-30	[4-(6-галоген-7-замещенные-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины и формы и способы, связанные с ними
UY26851A1 (es)	2002-01-31	Derivados de la 4-fenilpiridina
NO20050664L (no)	2005-04-15	2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
MXPA04003611A (es)	2004-07-30	Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
ID25478A (id)	2000-10-05	Agonis 5-ht1f
ITMI20011284A0 (it)	2001-06-19	Composizione farmaceutica per il trattamento dell'iperfosfatemia
DE602004028113D1 (de)	2010-08-26	Verwendung von 2,3-Dehydronaringenin-Derivaten zur Behandlung von Entzündungsprozessen und diese Derivate enthaltende pharmazeutische Zusammensetzung
ATE327240T1 (de)	2006-06-15	2ß OXO-VORUSCHARIN UND DERIVATEN
PT1370526E (pt)	2006-08-31	Diamidas que inibem a actividade da triptase e do factor xa